Outlook Therapeutics, Inc. OTLK
0.64
(0.02)
(3.03%)
as of 25 Sep
- Market cap
- $159.5M
- P/E
- 0.0×
Follow OTLK
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 256.92% | 198.37% | 231.56% | 118.61% |
+8 more TTM periods Free account |
|
| (251.66%) | (297.58%) | (583.69%) | (263.36%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
1,109.13% | 339.04% | 322.56% | 219.61% | |
Average Days of Receivables |
(515.83) | 2,980.27 | 6.90 | 69.32 | |
Free Cash Flow per Share |
(0.41) | (0.57) | (0.93) | (1.49) | |
Free Cash Flow |
(56.15) | (47.05) | (55.80) | (51.83) | |
Piotroski F-Score |
4.00 | 2.00 | 2.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(294.37%) | (822.13%) | (822.07%) | (887.13%) | |
Accounts Receivable Turnover |
(0.69) | 0.24 | 18.29 | 3.15 | |
Accounts Payable Turnover |
0.13 | 0.14 | 0.14 | 0.15 | |
Inventory Turnover |
0.24 | 0.44 | 0.43 | 0.00 | |
Average Days of Payables |
2,233.61 | 3,241.97 | 1,912.02 | 2,698.36 | |
Days of Inventory on Hand |
1,654.87 | 795.10 | 903.45 | 883.82 | |
Tax Rate |
0.00 | 0.00 | 0.00 | (0.02) | |
Research and Development Expense of Revenue |
(1,492.46%) | 6,378.99% | 349.14% | 346.22% | |
Selling, General and Administrative Expense of Revenue |
(3,093.68%) | 11,445.12% | 604.10% | 508.72% | |
Share Based Compensation of Revenue |
(365.35%) | 1,543.47% | 100.78% | 113.34% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.92 | 0.77 | 0.54 | 0.83 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
(0.01) | 0.00 | 0.10 | 0.23 | |
Operating CF per Share |
(0.41) | (0.57) | (0.93) | (1.49) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
5,253.40% | (18,299.76%) | (1,697.59%) | (795.14%) |
Columns are period end dates